Levels of systemic inflammatory markers were reduced following 16 weeks of secukinumab treatment in patients with moderate to severe HS.
Among patients with GCA, those with low vs high CRP levels more often presented with anterior ischemic optic neuropathy and limb claudication.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback